356 related articles for article (PubMed ID: 35278076)
21. Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma.
Kawachi H; Kunimasa K; Kukita Y; Nakamura H; Honma K; Kawamura T; Inoue T; Tamiya M; Kuhara H; Nishino K; Mizote Y; Akazawa T; Tahara H; Kumagai T
Immunotherapy; 2021 Jul; 13(10):799-806. PubMed ID: 34030451
[TBL] [Abstract][Full Text] [Related]
22. B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma.
Yamada T; Miki Y; Suzuki M; Kondoh O; Saito-Koyama R; Ono K; Okada Y; Sasano H
Cancer Med; 2022 Jan; 11(2):479-491. PubMed ID: 34907653
[TBL] [Abstract][Full Text] [Related]
23. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
24. Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in
Isomoto K; Haratani K; Hayashi H; Shimizu S; Tomida S; Niwa T; Yokoyama T; Fukuda Y; Chiba Y; Kato R; Tanizaki J; Tanaka K; Takeda M; Ogura T; Ishida T; Ito A; Nakagawa K
Clin Cancer Res; 2020 Apr; 26(8):2037-2046. PubMed ID: 31937613
[TBL] [Abstract][Full Text] [Related]
25. Thoracic SMARCA2-deficient But SMARCA4-preserved Tumors With Undifferentiated Morphology Combined With Claudin-4 Negativity.
Iwakoshi A; Sasaki E; Sato M; Sugiyama K; Kogure Y; Kitagawa C; Nishimura R
Am J Surg Pathol; 2022 Jul; 46(7):1000-1006. PubMed ID: 35220352
[TBL] [Abstract][Full Text] [Related]
26. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.
Starzer AM; Berghoff AS; Hamacher R; Tomasich E; Feldmann K; Hatziioannou T; Traint S; Lamm W; Noebauer-Huhmann IM; Furtner J; Müllauer L; Amann G; Bauer S; Schildhaus HU; Preusser M; Heller G; Brodowicz T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762319
[TBL] [Abstract][Full Text] [Related]
27. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
[TBL] [Abstract][Full Text] [Related]
29. A Subset of Thoracic SMARCA4-Deficient Undifferentiated Tumors Express GATA3.
Coconubo DM; Wangsiricharoen S; Pettus JR; Linos K; Pinto A; Wang WL; Kerr DA; Cloutier JM
Int J Surg Pathol; 2024 Jun; 32(4):684-691. PubMed ID: 37461275
[TBL] [Abstract][Full Text] [Related]
30. SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior.
Sauter JL; Graham RP; Larsen BT; Jenkins SM; Roden AC; Boland JM
Mod Pathol; 2017 Oct; 30(10):1422-1432. PubMed ID: 28643792
[TBL] [Abstract][Full Text] [Related]
31. Cytopathological Features of
Takeda M; Tani Y; Saijo N; Shimizu S; Taniguchi Y; Otsuka K; Nakao K; Tamiya A; Okishio K; Atagi S; Ohbayashi C; Kasai T
Int J Surg Pathol; 2020 Feb; 28(1):109-114. PubMed ID: 31448657
[No Abstract] [Full Text] [Related]
32. Diagnosis of thoracic SMARCA4-deficient undifferentiated tumor in cytology.
Kezlarian B; Montecalvo J; Bodd FM; Chang JC; Riedel E; White C; Rekhtman N; Sauter JL
Cancer Cytopathol; 2023 Aug; 131(8):526-534. PubMed ID: 37278102
[TBL] [Abstract][Full Text] [Related]
33. SMARCA4-deficient undifferentiated tumor that responded to chemotherapy in combination with immune checkpoint inhibitors: A case report.
Utsumi T; Taniguchi Y; Noda Y; Fukai M; Kibata K; Murakawa T
Thorac Cancer; 2022 Aug; 13(15):2264-2266. PubMed ID: 35778998
[TBL] [Abstract][Full Text] [Related]
34. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
[TBL] [Abstract][Full Text] [Related]
35. [SMARCA4-deficient thoracic tumors: A new entity].
Decroix E; Leroy K; Wislez M; Fournel L; Alifano M; Damotte D; Mansuet-Lupo A
Bull Cancer; 2020 Jan; 107(1):41-47. PubMed ID: 31916995
[TBL] [Abstract][Full Text] [Related]
36. Update on genetically defined lung neoplasms: NUT carcinoma and thoracic SMARCA4-deficient undifferentiated tumors.
Chatzopoulos K; Boland JM
Virchows Arch; 2021 Jan; 478(1):21-30. PubMed ID: 33409598
[TBL] [Abstract][Full Text] [Related]
37. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition.
Alessi JV; Ricciuti B; Spurr LF; Gupta H; Li YY; Glass C; Nishino M; Cherniack AD; Lindsay J; Sharma B; Felt KD; Rodig SJ; Cheng ML; Sholl LM; Awad MM
J Thorac Oncol; 2021 Jul; 16(7):1176-1187. PubMed ID: 33845210
[TBL] [Abstract][Full Text] [Related]
38. Recent updates in thoracic SMARCA4-deficient undifferentiated tumor.
Nambirajan A; Jain D
Semin Diagn Pathol; 2021 Sep; 38(5):83-89. PubMed ID: 34147303
[TBL] [Abstract][Full Text] [Related]
39. An aggressive case of a thoracic undifferentiated SMARCA4-deficient tumor with extensive pleural involvement.
Hanona PF; Ezekwudo D; Fullmer J; Allen T; Jaiyesimi I
Thorac Cancer; 2024 Apr; 15(10):847-851. PubMed ID: 38390699
[TBL] [Abstract][Full Text] [Related]
40. Usefulness of cell block examination for the cytological diagnosis of thoracic SMARCA4-deficient undifferentiated tumor: A case report.
Minoshima A; Sugita S; Segawa K; Aoyama T; Ito M; Daimon F; Takenami T; Kido T; Moriya J; Nishikiori H; Hasegawa T
Diagn Cytopathol; 2023 May; 51(5):E149-E154. PubMed ID: 36772934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
